Hansa Biopharma AB's total assets for Q4 2024 were kr800.64M, a decrease of -14.89% from the previous quarter. SE:HNSA total liabilities were kr1.39B for the fiscal quarter, a 10.26% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.